Host cellular protein substrates of SARS-CoV-2 proteases [Added supplements: Sex as biological variable supplement, COVID-19 Variant Supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170636, 171493, 175518

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $306,348.4
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Pending
  • Research Location

    Canada
  • Lead Research Institution

    University of British Columbia
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The recent outbreak of coronavirus SARS-CoV-2 (2019-2020) leading to COVID-19 disease in China and worldwide has led to increased urgency in identifying strategies to mitigate the spread of coronavirus infection and treat infected individuals. No established treatments exist, thus there is a need to identify antiviral targets. As evidenced of recurring SARS-CoV (2003) and MERS-CoV (2012) outbreaks, there is also a need for long-term preparations to counteract future emerging coronavirus outbreaks. Currently, the pathogenic mechanisms that lead to COVID-19 and related SARS/MERS-CoV diseases are not understood. In this study, we will identify the host proteins that are targeted by a viral protein called a protease using an unbiased proteomics approach. Identifying the protein targets of SARS/MERS-CoV proteases will reveal into the protein sequence that binds to the proteases. We will engineer and optimize decoy protein sequences that will effectively block SARS/MERS-CoV protease function and thus, inhibit SARS/MERS-CoV infection. Uncovering the proteins that are targeted by the SARS/MERS-CoV proteases will also provide a catalog of the host processes that these viruses affect, thus gaining insights into the pathogenic mechanisms that lead to COVID-19 disease.